Strides Pharma Science shares jump 9% after USFDA EIR for Bengaluru facility

This positive development followed the US Food and Drug Administration (US FDA) issuing an Establishment Inspection Report (EIR) for the facility, bringing the regulatory inspection to a close.

According to the company’s stock exchange filing, the USFDA conducted a current Good Manufacturing Practices (cGMP) inspection at the facility from May 12 to May 20, 2026. The inspection concluded with a Form 483 containing five observations, to which Strides submitted a comprehensive response within the stipulated timeframe.

Following a review of the company’s responses and the corrective and preventive actions implemented, the USFDA classified the inspection outcome as Voluntary Action Indicated (VAI) and issued the EIR, effectively concluding the inspection process.

The Bengaluru facility is Strides’ flagship manufacturing site and caters to regulated as well as other international markets. It manufactures a wide range of pharmaceutical dosage forms, including tablets, capsules and oral liquids, supporting both existing commercial products and the company’s future growth plans.

Live Events

Strides said the successful closure of the inspection further strengthens its regulatory track record and reinforces its commitment to maintaining high-quality standards across its global operations.

Stock Performance and Valuation

The USFDA development comes as a relief for investors after a period of weakness in the stock. Before Thursday’s sharp recovery, Strides Pharma Science shares had declined around 10% over the past month and nearly 16% over the last three months. At Thursday’s level, the company’s market capitalisation stood at approximately Rs 8,825 crore, while the stock’s 52-week high is Rs 1,231.On the valuation front, Strides Pharma Science is currently trading at a price-to-earnings (P/E) ratio of 14.26, while its price-to-sales ratio stands at 1.78 and price-to-book ratio at 2.78.

Technical Indicators

Technically, the stock continues to show signs of recent weakness despite Thursday’s strong rebound. Its 14-day Relative Strength Index (RSI) stands at 36.3. An RSI below 30 generally indicates oversold conditions, while a reading above 70 is viewed as overbought.

The stock is currently trading above six of its eight key Simple Moving Averages (SMAs), while remaining below its 50-day and 100-day SMAs. The technical setup suggests that Thursday’s rally could mark an attempt at recovery, although the stock still needs to regain key moving-average levels to establish stronger upward momentum.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)